DSGNDesign Therapeutics, Inc.
$11.49+77% 1Y
$11.49
$5.5352 weeks$15.94
The financials
Design Therapeutics, Inc. by the numbers
Design Therapeutics, Inc. (DSGN) reported revenue of $0 in Q2 2026 (quarter ended Jun 30, 2026). That came with net loss of $20M. For the full year FY2025, revenue was $0 and net income −$70M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | n/a |
| Operating income | −$22M | −$22M | n/a |
| Net income | −$20M | −$19M | n/a |
| Diluted EPS | −$0.32 | −$0.34 | n/a |